PMID: 6413058Jan 1, 1983Paper

Phase I evaluation of oral tegafur

Cancer Treatment Reports
A Y BedikianM A Burgess

Abstract

A phase I clinical study of tegafur (ftorafur) was conducted in 29 patients with various advanced solid tumors. To evaluate its efficacy and toxicity, the initial dose of 0.5 g/m2/day x 21 days at 3-week intervals was progressively increased to a maximum dose of 1.5 g/m2/day. Tegafur was administered orally in two or three divided doses. Diarrhea was the dose-limiting toxic effect and occurred more often in patients with abnormal pretreatment liver function. Nausea occurred in about one-half of the patients, but vomiting was infrequent. Skin rash and mucositis occurred in 10% and 7% of the patients, respectively. Neurologic toxic effects of tegafur were infrequent and mild. The hematologic toxicity of tegafur was minimal. Antitumor activity could be evaluated in 21 patients with measurable disease. One complete and three partial responses were observed in four of 17 patients who had adenocarcinoma of unknown primary origin. All responses occurred at doses greater tan or equal to 1.0 g/m2/day. The recommended dose of tegafur for this schedule of administration is 1.0 g/m2/day.

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Gan to kagaku ryoho. Cancer & chemotherapy
K MatsuiS Kudoh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
F J AnsfieldJ P Singson
© 2021 Meta ULC. All rights reserved